Ravindra Prasad Thokala: When T Cells Heal and Harm in the Same Transplant Unit
Ravindra Prasad Thokala, Transfusion Medicine Consultant and Head at Apollo Cancer Center, shared a post on LinkedIn:
“Two patients, two cell therapies, two opposite ends of the same immune system — and a striking reminder of why this cellular therapy is equal parts thrilling and humbling.
The first: adenovirus-specific T cells (CD4 and CD8) at a 5 million cell dose, prepared against refractory adenoviremia after a stem cell transplant, when the patient’s own reconstituting immunity and neither the list of antivirals simply cannot control the virus.
With turnaround — under 36 hours from leukapheresis to infusion (helped by Cytocare technologies for such a processing in the shortest time) — because in this race that speed can be the difference between staying ahead of the virus and forever chasing it.
The second: extracorporeal photopheresis for aggressive (fiery) acute skin GvHD, where the problem is the exact opposite — donor T cells that have turned on the patient’s own tissue, leaving the skin you see here.
Rather than simply suppressing those cells, photopheresis collects, treats and returns them in a way that tames the T cells gone rogue , same time gently retrains the immune response.
One therapy adds T cells to deliver might Against a virus; the other tames T cells that target the host — same cells, opposite missions, one shared goal of carrying a transplant patient safely through.
This is the reality of cellular therapy:
You would never wish either situation on a patient, but working in this space … you will eventually meet both.
Grateful to a team that can pivot between building immunity and calming it, sometimes on the very same day — and now we wait, watch and hope for both responses.”

Stay updated with Hemostasis Today.
-
Jul 15, 2026, 15:44Josepha Clara Sedzro: Celebrating a Proud Moment of Our Research Journey at ISTH 2026
-
Jul 15, 2026, 15:33Louise St. Germain Bannon: Honouring the People and Partnerships Behind ISTH 2026
-
Jul 15, 2026, 15:28Jeff Schaffnit: Sanofi Highlights Progress in Hemophilia and ITP at ISTH 2026
-
Jul 15, 2026, 15:25Ganesh Mohan: Presenting the Manipal TMA Registry on the Global Stage at ISTH 2026
-
Jul 15, 2026, 15:20Dino Mehic: Presenting New Insights into Thrombin Generation at ISTH 2026
-
Jul 15, 2026, 15:16Mouna Sassi: Turning Scientific Discussion into Better Patient Care at ISTH 2026
-
Jul 15, 2026, 15:11Joseph R. Shaw: Honoured to Be Recognised as a Top Peer Reviewer for JTH at ISTH 2026
-
Jul 15, 2026, 14:27Factor XIII and the Future of Anticoagulation in VTE
-
Jul 15, 2026, 14:26Matthew D. Neal: From Platelet Biology to Patient Impact at ISTH 2026